Earnings Call Intelligence Subscribe
Home › Call Sheets › DHR › Q4'25
Call sheet · Q4'25

Danaher (DHR)

Q4'25 earnings call · held January 28, 2026 · compared with the Q3'25 call · management-credibility review
10/12
Disclosure score
3 medium, 4 low flags
Financial quality
Bottom line
The sleeper story is bioprocessing equipment quietly inflected to growth after 18 months of declines, with three consecutive quarters of order growth that management buried in guidance conservatism. The obvious headline is solid Q4 execution, but the binding constraint remains academic funding paralysis that's preventing Life Sciences from capitalizing on pharma recovery. Respiratory revenue guidance revision to $1.8B reflects permanent demand destruction masquerading as seasonal adjustment. Rainer's most telling quote: 'One quarter of growth, we are not ready to call that a trend yet' - classic DHR under-promise behavior. My view changes if equipment orders accelerate meaningfully in Q1 or academic funding shows signs of life beyond pharma.

The 30-second version

  • Bioprocessing equipment quietly inflected to growth after 18 months of declines
  • Respiratory revenue guidance cut by $100M reflects endemic reality, not seasonal weakness
  • Life Sciences flatlining despite three quarters of pharma recovery

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$6.1B (+3% YoY)$6.8B (+2.5% YoY)50bps deceleration but beat expectations
Core Revenue Growth3.0%2.5%50bps slowdown
Adjusted EPS$1.89 (+10% YoY)$2.23 (+4% YoY)600bps deceleration in growth rate
Bioprocessing Core GrowthHigh single digitsHigh single digitsStable momentum maintained
Bioprocessing EquipmentHigh teens declineMid-single digit growthMassive inflection from decline to growth
Life Sciences Core Growth-1.0%+0.5%150bps improvement but still anemic
Diagnostics Core Growth3.5%2.0%150bps deceleration
Respiratory RevenueExceeded expectations$500M (Q4), guiding $1.8B 2026$100M cut from prior year expectations
Adjusted Operating Margin27.9% (+40bps YoY)28.3% (-130bps YoY)170bps sequential deterioration
Free Cash Flow$1.4B (Q3)$1.8B (Q4)$400M sequential improvement

Accountability tracked

8 new promises made5 narrative shifts flagged7 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full DHR Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.